Skip to content

CROI: Once daily Kaletra tablets non-inferior to twice daily dose

CROI: Nanoparticle technology creates a once-a-month HIV drug

CROI: Darunavir found effective and tolerable in treatment-experienced children and adolescents at 24 weeks

CROI: CCR5 antagonist SCH532706 shows potent activity and good tolerability in small trial

CROI: Vicriviroc appears safe and effective at higher doses in treatment-experienced patients after 48 weeks

Maraviroc to be developed as a microbicide

Key European committee gives the nod to new Kaletra tablet for kids

Raltegravir now available for UK patients

Etravirine (TMC125, Intelence) granted accelerated approval in US